Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
27.7M
-
Shares change
-
+9.01M
-
Total reported value, excl. options
-
$314M
-
Value change
-
+$101M
-
Number of buys
-
39
-
Number of sells
-
-30
-
Price
-
$11.34
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q1 2020
83 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q1 2020.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.7M shares
of 77.3M outstanding shares and own 35.81% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (2.77M shares), BVF INC/IL (2.67M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.03M shares), Consonance Capital Management LP (1.98M shares), ORBIMED ADVISORS LLC (1.66M shares), FMR LLC (1.59M shares), Aquilo Capital Management, LLC (1.5M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.27M shares), Capital International Investors (1.06M shares), and NEA Management Company, LLC (992K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.